THURSDAY, May 15, 2025 (HealthDay News) -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity ...

Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB, suggesting that its action contributes to alteration in postprandial glucose regulation.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Still, it was not until 1973 and 1987 that glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were discovered and characterized.

Key takeaways: Results showed 14 days may be the optimal cutoff for glucagon-like peptide-1 receptor agonists prior to hip or knee arthroplasty.

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.Results showed ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Medicine, lifestyle changes, and surgery can return glucose levels to normal or nearly normal in some type 2 diabetes ...

Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...

Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric metabolic surgery. (HealthDay News) — Glucagon-like peptide-1 receptor ...